S&P 5007,651.54▼0.2% Nasdaq26,861.06▲0.2% Dow50,906.05▼0.9% Russell 2K2,796.86▼0.4% 10-Yr5.29%+4bp VIX16.34+0.30 WTI$90.46▲1.2% Gold$4,189.00▲0.2% EUR/USD1.133▼0.3% BTC$86,682▲2.2% Nikkei65,481▼0.6%
At close · Wed, Sep 30, 2026
Daily Market Updates.

Global Markets

Home›Global Markets›China›Big biopharma increasingly looks to China for new drugs

Big biopharma increasingly looks to China for new drugs

Reported · Written up by our desk · China

CNBC World reports that Western biopharma companies are turning to China to source new drug innovation as a major patent cliff approaches.

The outlet says the shift is being driven by expectations that patents held by pharma firms will expire over the coming period, pushing companies to pursue multibillion-dollar deals tied to new pipelines.

← Newer storyBitcoin trades near $87,000 after U.S. jobs data miss

More like this

Global MarketsAirport Authority ends nearly 50-year deal over 11 Skies project
Global MarketsBig Pharma expands China innovation deals as patent cliff nears
Global MarketsHong Kong IPO debuts slump as investor appetite fades
Global MarketsChina scientists report crop yield gains from mineralized irrigation water
Global MarketsHong Kong retail sales rise 5.6% year on year in August

Sources

CNBC WorldBig Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.